Candesant Biomedical Announces $35M in Series B Financing to Advance Commercialization of Brella™, the First and Only FDA-cleared 3-Minute SweatControl Patch™
/
DateJun 06 2023
NASHVILLE, Tenn., June 6, 2023 /PRNewswire/ — Candesant Biomedical, Inc. (“Candesant”), a private medical device company focused on the development and commercialization of non-invasive treatments... Read More →